Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine
I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...
Billed as nonaddictive, new pain pill could soon win FDA approval
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.
Lost Money on Vertex Pharmaceuticals Incorporated(VRTX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
7 Best Biotech Stocks to Buy for 2025
The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...
BioPharma Dive6d
Kidney disease drugmaker Maze files for IPO
Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised ...
Vertex Grapples With Bearish Chart As Death Cross Emerges
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.
Vertex Pharmaceuticals, Orna Therapeutics announce research collaboration
Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with ...
Cancer Research UK15d
A trial looking at a test to predict who might benefit from chemotherapy for breast cancer (OPTIMA)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available. Chemotherapy followed by hormone therapy is often used after surgery for breast cancer to ...
Hosted on MSN19d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...